Cancer molecular subtyping using limited multi-omics data with missingness
Fig 6
The relationship among CancerSD outcomes, mRNAsi scores, and patient clinical characteristics.
(a) An overview of the association between the mRNAsi and clinical features. The median of mRNAsi score is used to categorize mRNAsi levels.(b) mRNAsi scores across different molecular subtypes.(c) Kaplan-Meier survival curves of different mRNAsi levels. Among them, HR and 95CI are abbreviations of Hazard Ratio and 95% Confidence Interval, respectively.(d) The relationship between CancerSD scores (with normalization) and mRNAsi scores in GC patients. The former is derived from the output of CancerSD before the softmax layer, while the latter is obtained through the mRNAsi model.(e) The integrated sankey diagram portrays the underlying correlations across the mRNAsi, molecular subtypes and Lauren classification.(f) mRNAsi scores across different Lauren subtypes.(g) The relationship between Integrated CancerSD Score (ICS) and mRNAsi scores in GC patients.(h) Kaplan-Meier survival curves of different ICS levels.(i) Correlation of mRNAsi and expression levels of important genes identified by CancerSD. The regression lines in figures are fitted by the corresponding data. The significance in the figure is estimated by pearson correlation coefficient.